Pharmacokinetics of antiretrovirals in mucosal tissue

Bibliography

• WHO | HIV/AIDS [Internet]. Available from: http://www.who.int/mediacentre/factsheets/fs360/en/ [Cited 5 November 2014]
   Google Scholar
• Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365(6):493-505
   PubMed Web of Science ®Google Scholar
• Key graphics from CDC analysis showing proportion of people engaged in each of the five main stages of HIV care [Internet]. 2013. Available from: http://www.cdc.gov/nchhstp/newsroom/2012/Continuum-of-Care-Graphics.html
   Google Scholar
• Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367(5):399-410
   PubMed Web of Science ®Google Scholar
• Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363(27):2587-99
   PubMed Web of Science ®Google Scholar
• Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in botswana. N Engl J Med 2012;367(5):423-34
   PubMed Web of Science ®Google Scholar
• Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in bangkok, thailand (the bangkok tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381(9883):2083-90
   PubMed Web of Science ®Google Scholar
• Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among african women. N Engl J Med 2012;367(5):411-22
   PubMed Web of Science ®Google Scholar
• Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: Daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003) [Abstract 26LB]. 20th Conference on Retroviruses and Opportunistic Infections. 3 – 6 March 2013; Atlanta, GA
   Google Scholar
• Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis 2014;14(9):820-9
   PubMed Web of Science ®Google Scholar
• Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr 2014;66(3):340-8
   PubMed Web of Science ®Google Scholar
• Trezza CR, Kashuba AD. Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention. Clin Pharmacokinet 2014;53(7):611-24
   PubMed Web of Science ®Google Scholar
• Keele BF, Estes JD. Barriers to mucosal transmission of immunodeficiency viruses. Blood 2011;118(4):839-46
   PubMed Web of Science ®Google Scholar
• Thompson CG, Cohen MS, Kashuba AD. Antiretroviral pharmacology in mucosal tissues. J Acquir Immune Defic Syndr 2013;63(Suppl 2):S240-7
   PubMedGoogle Scholar
• Schmidt S, Gonzalez D, Derendorf H. Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci 2010;99(3):1107-22
   PubMed Web of Science ®Google Scholar
• Boffito M, Back DJ, Blaschke TF, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003;19(9):825-35
   PubMed Web of Science ®Google Scholar
• Salas Herrera IG, Pearson RM, Turner P. Quantitation of albumin and alpha-1-acid glycoprotein in human cervical mucus. Hum Exp Toxicol 1991;10(2):137-9
   PubMed Web of Science ®Google Scholar
• Selzentry full prescribing information. ViiV Healthcare; Research Triangle Park, NC 27709: 2014
   Google Scholar
• Dumond JB, Patterson KB, Pecha AL, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr 2009;51(5):546-53
   PubMed Web of Science ®Google Scholar
• Fischl MA, Richman DD, Flexner C, et al. Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15(1):28-34
   PubMedGoogle Scholar
• Lazdins JK, Mestan J, Goutte G, et al. In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. J Infect Dis 1997;175(5):1063-70
   PubMed Web of Science ®Google Scholar
• Kempf D, Hickman D, Vasavanonda S, et al. Identification of the serum-free IC50 for lopinavir and ritonavir: a useful measure for the estimation of inhibitory quotients into plasma and sanctuary sites. abstract 3.3. 3rd International Workshop on Clinical Pharmacology of HIV Therapy, Washington DC; 2002
   Google Scholar
• Avery LB, Zarr MA, Bakshi RP, et al. Increasing extracellular protein concentration reduces intracellular antiretroviral drug concentration and antiviral effect. AIDS Res Hum Retroviruses 2013;29(11):1434-42
   PubMed Web of Science ®Google Scholar
• Kis O, Robillard K, Chan GN, Bendayan R. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci 2010;31(1):22-35
   PubMed Web of Science ®Google Scholar
• Zhou T, Hu M, Cost M, et al. Short communication: expression of transporters and metabolizing enzymes in the female lower genital tract: Implications for microbicide research. AIDS Res Hum Retroviruses 2013;29(11):1496-503
   PubMed Web of Science ®Google Scholar
• Hilgendorf C, Ahlin G, Seithel A, et al. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 2007;35(8):1333-40
   PubMed Web of Science ®Google Scholar
• Nicol MR, Fedoriw Y, Mathews M, et al. Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention. J Clin Pharmacol 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Thompson CG, Sedykh A, Nicol MR, et al. Short communication: cheminformatics analysis to identify predictors of antiviral drug penetration into the female genital tract. AIDS Res Hum Retroviruses 2014;30(11):1058-64
   PubMed Web of Science ®Google Scholar
• van de Ven R, Oerlemans R, van der Heijden JW, et al. ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer. J Leukoc Biol 2009;86(5):1075-87
   PubMed Web of Science ®Google Scholar
• Yamamoto-Furusho JK, Villeda-Ramirez MA, Fonseca-Camarillo G, et al. High gene expression of MDR1 (ABCB1) is associated with medical treatment response and long-term remission in patients with ulcerative colitis. Inflamm Bowel Dis 2010;16(4):541-2
   PubMed Web of Science ®Google Scholar
• Poller B, Drewe J, Krahenbuhl S, et al. Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. Cell Mol Neurobiol 2010;30(1):63-70
   PubMed Web of Science ®Google Scholar
• Blokzijl H, Vander Borght S, Bok LI, et al. Decreased P-glycoprotein (P-gp/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels. Inflamm Bowel Dis 2007;13(6):710-20
   PubMed Web of Science ®Google Scholar
• Herold BC, Keller MJ, Shi Q, et al. Plasma and mucosal HIV viral loads are associated with genital tract inflammation in HIV-infected women. J Acquir Immune Defic Syndr 2013;63(4):485-93
   PubMed Web of Science ®Google Scholar
• Majcher-Peszynska J, Haase G, Sass M, et al. Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections. Eur J Clin Pharmacol 2008;64(11):1093-100
   PubMed Web of Science ®Google Scholar
• Kashuba AD, Nafziger AN. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet 1998;34(3):203-18
   PubMed Web of Science ®Google Scholar
• Shen Z, Fahey JV, Rodriguez-Garcia M, et al. Female sex hormone regulation of tenofovir-diphosphate in human female reproductive tract (FRT) cells in culture. AIDS Res Hum Retroviruses 2014;30(Suppl 1):A149-50
   Google Scholar
• Axiotis CA, Guarch R, Merino MJ, et al. P-glycoprotein expression is increased in human secretory and gestational endometrium. Lab Invest 1991;65(5):577-81
   PubMed Web of Science ®Google Scholar
• Sheth AN, Evans-Strickfaden T, Haaland R, et al. HIV-1 genital shedding is suppressed in the setting of high genital antiretroviral drug concentrations throughout the menstrual cycle. J Infect Dis 2014;210(5):736-44
   PubMed Web of Science ®Google Scholar
• Mitchell C, Roemer E, Nkwopara E, et al. Correlation between plasma, intracellular, and cervical tissue levels of raltegravir at steady-state dosing in healthy women. Antimicrob Agents Chemother 2014;58(6):3360-5
   PubMed Web of Science ®Google Scholar
• Greener BN, Patterson KB, Prince HM, et al. Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing. J Acquir Immune Defic Syndr 2013;64(1):39-44
   PubMed Web of Science ®Google Scholar
• Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). Antivir Ther 2011;16(8):1139-47
   PubMed Web of Science ®Google Scholar
• Sharma PL, Nurpeisov V, Hernandez-Santiago B, et al. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Curr Top Med Chem 2004;4(9):895-919
   PubMed Web of Science ®Google Scholar
• Dumond JB, Yeh RF, Patterson KB, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS 2007;21(14):1899-907
   PubMed Web of Science ®Google Scholar
• Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011;3(112):112re4
   PubMed Web of Science ®Google Scholar
• Robbins BL, Srinivas RV, Kim C, et al. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 1998;42(3):612-17
   PubMed Web of Science ®Google Scholar
• Cottrell ML, Prince HMA, Sykes C, et al. Mucosal tissues in women exhibit different concentrations of endogenous nucleotides and intracellular and extracellular antiretroviral (ARV) concentrations: Implications for preexposure prophylaxis (PrEP) development [Abstract TUPE011]. 20th International AIDS Conference; 20 – 25 July 2014; Melbourne, Australia
   Google Scholar
• Louissaint NA, Cao YJ, Skipper PL, et al. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res Hum Retroviruses 2013;29(11):1443-50
   PubMed Web of Science ®Google Scholar
• Schwartz JL, Rountree W, Kashuba AD, et al. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One 2011;6(10):e25974
   PubMed Web of Science ®Google Scholar
• Anton PA, Cranston RD, Kashuba A, et al. RMP-02/MTN-006: a phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses 2012;28(11):1412-21
   PubMed Web of Science ®Google Scholar
• Hendrix CW, Chen BA, Guddera V, et al. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One 2013;8(1):e55013
   PubMed Web of Science ®Google Scholar
• Yang KH, Hendrix C, Bumpus N, et al. A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate. PLoS One 2014;9(10):e106196
   PubMedGoogle Scholar
• Min SS, Corbett AH, Rezk N, et al. Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. J Acquir Immune Defic Syndr 2004;37(5):1577-80
   PubMed Web of Science ®Google Scholar
• Sustiva Full Prescribing Information. Bristol-Myers Squibb Co., Princeton, NJ 08543 USA; 2014
   Google Scholar
• Viramune Full Prescribing Information. Ridgefield, CT 06877 USA: Boehringer Ingelheim Pharmaceuticals, Inc; 2014
   Google Scholar
• Rescriptor Full Prescribing Information. ViiV Healthcare, Research Triangle Park, NC 27709; 2012
   Google Scholar
• Clavel C, Peytavin G, Tubiana R, et al. Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study. Antimicrob Agents Chemother 2012;56(7):4018-20
   PubMed Web of Science ®Google Scholar
• Brown KC, Patterson KB, Jennings SH, et al. Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men. J Acquir Immune Defic Syndr 2012;61(2):138-44
   PubMed Web of Science ®Google Scholar
• Jackson AG, Else LJ, Mesquita PM, et al. A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis. Clin Pharmacol Ther 2014;96(3):314-23
   PubMed Web of Science ®Google Scholar
• Phase II safety and acceptability of an investigational injectable product, TMC278LA, for pre-exposure prophylaxis - full text view - ClinicalTrials.gov [Internet]. Available from: http://clinicaltrials.gov/ct2/show/NCT02165202?term=rilpivirine+AND+long+acting&rank=5 [Cited 4 December 2014]
   Google Scholar
• MTN-013/IPM 026 | microbicide trials network [Internet]. Available from: http://www.mtnstopshiv.org/news/studies/mtn013 [Cited 21 November 2014]
   Google Scholar
• Chen BA, Panther L, Hoesley C, et al. Safety and pharmacokinetics/pharmacodynamics of dapivirine and maraviroc vaginal rings, [Abstract 41]. 21st Conference on Retroviruses and Opportunistic Infections; 3 – 6 March 2014; Boston, MA
   Google Scholar
• Bunge K, Dezzutti CS, Macio I, et al. FAME-02: A phase I trial to assess safety, PK, and PD of gel and film formulations of dapivirine [Abstract 42LB]. 21st Conference on Retroviruses and Opportunistic Infections. 3 – 6 March 2014; Boston, MA
   Google Scholar
• Isentress full prescribing information. Merck & Co., Inc, Whitehouse Station, NJ 08889, USA; 2014
   Google Scholar
• Patterson KB, Prince HA, White N, et al. Pharmacokinetics (PK) of raltegravir (RAL) in the blood plasma (BP) and genital tract (GT) in HIV+ and HIV- women. 5th Reviews in Antiviral Therapy and Infectious Diseases 2010;7(16):abstract O17
   Google Scholar
• Clavel C, Peytavin G, Tubiana R, et al. Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study). Antimicrob Agents Chemother 2011;55(6):3018-21
   PubMed Web of Science ®Google Scholar
• Hashiguchi Y, Hamada A, Shinohara T, et al. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents. Biochem Biophys Res Commun 2013;439(2):221-7
   PubMed Web of Science ®Google Scholar
• Adams JL, Patterson KB, Prince HM, et al. Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV negative women. Antivir Ther 2013;18(8):1005-13
   PubMed Web of Science ®Google Scholar
• Tivicay full prescribing information. ViiV Healthcare, Research Triangle Park, NC 27709; 2014
   Google Scholar
• Patterson KB, Prince HA, Stevens T, et al. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. AIDS 2013;27(9):1413-19
   PubMed Web of Science ®Google Scholar
• Cottrell ML, Prince HMA, Sykes C, et al. Mucosal tissue pharmacokinetics of maraviroc and raltegravir in women: implications for chemoprophylaxis [Abstract O_08]. 15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy; 19 – 21 May 2014; Washington DC, USA
   Google Scholar
• Spreen WR, Margolis DA, Pottage JCJr. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS 2013;8(6):565-71
   PubMed Web of Science ®Google Scholar
• AIDS info drug database-cabotegravir [Internet]. 2014. Available from: http://aidsinfo.nih.gov/drugs/513/cabotegravir/0/professional
   Google Scholar
• Spreen W, Ford SL, Chen S, et al. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr 2014;67(5):481-6
   PubMed Web of Science ®Google Scholar
• Radzio J, Spreen WR, Yueh YL, et al. Monthly GSK744 long-acting injections protect macaques against repeated vaginal SHIV exposures [Oral abstract 40LB]. 21st Conference on Retrovirus and Opportunistic Infections; 3 – 6 March 2014; Boston, MA
   Google Scholar
• Andrews CD, Spreen WR, Mohri H, et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science 2014;343(6175):1151-4
   PubMed Web of Science ®Google Scholar
• Spreen B, Rinehart A, Smith K, et al. HIV PrEP dose rationale for cabotegravir (GSK1265744) long-acting injectable nanosuspension. AIDS Res Hum Retroviruses 2014;30(Suppl 1):A12
   Google Scholar
• Griffin L, Annaert P, Brouwer KL. Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. J Pharm Sci 2011;100(9):3636-54
   PubMed Web of Science ®Google Scholar
• Launay O, Tod M, Louchahi K, et al. Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women. Antimicrob Agents Chemother 2004;48(2):632-4
   PubMed Web of Science ®Google Scholar
• Patterson K, Jennings S, Falcon R, et al. Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women. Antimicrob Agents Chemother 2011;55(3):1120-2
   PubMed Web of Science ®Google Scholar
• Anderson PL, Brundage RC, Bushman L, et al. Indinavir plasma protein binding in HIV-1-infected adults. AIDS 2000;14(15):2293-7
   PubMed Web of Science ®Google Scholar
• Fletcher CV, Staskus K, Wietgrefe SW, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci USA 2014;111(6):2307-12
   PubMed Web of Science ®Google Scholar
• Kline C, Ndjomou J, Franks T, et al. Persistence of viral reservoirs in multiple tissues after antiretroviral therapy suppression in a macaque RT-SHIV model. PLoS One 2013;8(12):e84275
   PubMedGoogle Scholar
• Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65(1):65-70
   PubMed Web of Science ®Google Scholar
• Brown KC, Patterson KB, Malone SA, et al. Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis 2011;203(10):1484-90
   PubMed Web of Science ®Google Scholar
• Abel S, Russell D, Whitlock LA, et al. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol 2008;65(Suppl 1):60-7
   PubMed Web of Science ®Google Scholar
• Chen BA, Panther L, Hoesley C, et al. Safety and pharmacokinetics/pharmacodynamics of dapivirine and maraviroc vaginal rings [Abstract 41]. 21st Conference on Retroviruses and Opportunistic Infections; 3 – 6 March 2014; Boston, MA
   Google Scholar
• Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in kampala, uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003;362(9387):859-68
   PubMed Web of Science ®Google Scholar
• Second european PrEP study closes placebo arm early due to high effectiveness [Internet]. 2014. Available from: http://www.aidsmap.com/Second-European-PrEP-study-closes-placebo-arm-early-due-to-high-effectiveness/page/2917367/
   Google Scholar
• Rajman I. PK/PD modelling and simulations: utility in drug development. Drug Discov Today 2008;13(7-8):341-6
   PubMed Web of Science ®Google Scholar
• Dezzutti CS, Hladik F. Use of human mucosal tissue to study HIV-1 pathogenesis and evaluate HIV-1 prevention modalities. Curr HIV/AIDS Rep 2013;10(1):12-20
   PubMedGoogle Scholar
• Arien KK, Kyongo JK, Vanham G. Ex vivo models of HIV sexual transmission and microbicide development. Curr HIV Res 2012;10(1):73-8
   PubMed Web of Science ®Google Scholar
• Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329(5996):1168-74
   PubMed Web of Science ®Google Scholar
• Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012;4(151):151ra125
   PubMed Web of Science ®Google Scholar
• Baheti G, Kiser JJ, Havens PL, Fletcher CV. Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. Antimicrob Agents Chemother 2011;55(11):5294-9
   PubMed Web of Science ®Google Scholar
• Cottrell M, Yang K, Prince H, et al. Predicting effective truvada® PrEP dosing strategies with a novel PK-PD model incorporating tissue active metabolites and endogenous nucleotides (EN) [Abstract OA22.06 LB]. HIV Research for Prevention: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIV R4P); 28 – 31 October 2014; Cape Town South Africa
   Google Scholar
• Garcia-Lerma JG, Aung W, Cong ME, et al. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J Virol 2011;85(13):6610-17
   PubMed Web of Science ®Google Scholar